Overview#
Shares of Amplifon, an Italian hearing care company, experienced a significant decline, reaching their lowest point in years. This drop was primarily triggered by the announcement of a €2.3 billion acquisition that investors believe could jeopardize the company's financial stability and diverge from its traditional retail-focused strategy.
Stock Performance#
On Tuesday, Amplifon’s stock fell by 11.5%, closing at €7.98. This followed a staggering 14.3% drop the previous day, marking the worst single-day loss for the company. Since February 17, when shares were priced at €13.69, the stock has plummeted over 41%.
Earnings Report and Acquisition Details#
The decline began on March 5, when Amplifon reported disappointing fourth-quarter earnings and withdrew its quantitative guidance for 2026. This news led to a 13.2% drop in stock price, with trading volume significantly higher than usual. Just over a week later, the company announced its plan to acquire GN Hearing for €2.3 billion, which will be financed through a combination of debt and new equity, raising concerns about the company's balance sheet.
Analyst Insights#
Despite the turmoil, Barclays maintained an “overweight” rating on Amplifon with a price target of €16, suggesting potential upside from the current stock price. However, they warned of short-term challenges, predicting a 3% dilution in earnings per share (EPS) in 2027, before a potential recovery in 2028 due to expected synergies from the acquisition. Barclays also noted that while the deal could benefit GN, it may negatively impact other hearing aid manufacturers that supply Amplifon.
Analysts have reduced their price target for Amplifon multiple times since May 2024, reflecting the stock's steep decline of over 75% from its peak earlier in the year.